Surveillance for recurrent head and neck cancer using positron emission tomography

Val Lowe, James H. Boyd, Frank R. Dunphy, Han Kim, T. Dunleavy, Brian T. Collins, David Martin, Brendan C. Stack, Chris Hollenbeak, J. W. Fletcher

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Purpose: Earlier detection of head and neck cancer recurrence may improve survival. We evaluated the ability of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) to detect recurrence in a prospective trial using sequential PET scans. Patients and Methods: Serial posttherapy FDG-PET was prospectively performed in 44 patients with stage III or IV head and neck cancer. PET was performed twice during the first posttreatment year (at 2 and 10 months after therapy) and thereafter as needed. After therapy, patients were grouped, based on tissue biopsies, into those who achieved a complete response (CR) and those who had residual disease (RD). Patients who achieved a CR were further grouped into those without evidence of disease and those who had recurrence by I year after completion of therapy. Disease status as determined by physical examination (PE), PET, and correlative imaging was compared. Results: Eight patients were lost to follow-up and six had RD after therapy. Of the remaining 30 patients with a CR, 16 had recurrence in the first year after therapy. Five of these 16 patients had recurrence detected by PET only, four by PET and correlative imaging only, five by PE and PET only, and two by PE, correlative imaging, and PET. Only PET detected all recurrences in the first year. PET performed better than correlative imaging (P = .013) or PE (P = .002) in the detection of recurrence. Conclusion: PET can detect head and neck tumor recurrence when it may be undetectable by other clinical methods. FDG-PET permits highly accurate detection of head and neck cancer recurrence in the posttherapy period. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)651-658
Number of pages8
JournalJournal of Clinical Oncology
Volume18
Issue number3
StatePublished - Feb 2000
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Positron-Emission Tomography
Recurrence
Physical Examination
Therapeutics
Lost to Follow-Up
Fluorodeoxyglucose F18
Early Detection of Cancer
Neck
Head
Biopsy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lowe, V., Boyd, J. H., Dunphy, F. R., Kim, H., Dunleavy, T., Collins, B. T., ... Fletcher, J. W. (2000). Surveillance for recurrent head and neck cancer using positron emission tomography. Journal of Clinical Oncology, 18(3), 651-658.

Surveillance for recurrent head and neck cancer using positron emission tomography. / Lowe, Val; Boyd, James H.; Dunphy, Frank R.; Kim, Han; Dunleavy, T.; Collins, Brian T.; Martin, David; Stack, Brendan C.; Hollenbeak, Chris; Fletcher, J. W.

In: Journal of Clinical Oncology, Vol. 18, No. 3, 02.2000, p. 651-658.

Research output: Contribution to journalArticle

Lowe, V, Boyd, JH, Dunphy, FR, Kim, H, Dunleavy, T, Collins, BT, Martin, D, Stack, BC, Hollenbeak, C & Fletcher, JW 2000, 'Surveillance for recurrent head and neck cancer using positron emission tomography', Journal of Clinical Oncology, vol. 18, no. 3, pp. 651-658.
Lowe V, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT et al. Surveillance for recurrent head and neck cancer using positron emission tomography. Journal of Clinical Oncology. 2000 Feb;18(3):651-658.
Lowe, Val ; Boyd, James H. ; Dunphy, Frank R. ; Kim, Han ; Dunleavy, T. ; Collins, Brian T. ; Martin, David ; Stack, Brendan C. ; Hollenbeak, Chris ; Fletcher, J. W. / Surveillance for recurrent head and neck cancer using positron emission tomography. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 3. pp. 651-658.
@article{dc4d11f06214476393a47fa303ce4886,
title = "Surveillance for recurrent head and neck cancer using positron emission tomography",
abstract = "Purpose: Earlier detection of head and neck cancer recurrence may improve survival. We evaluated the ability of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) to detect recurrence in a prospective trial using sequential PET scans. Patients and Methods: Serial posttherapy FDG-PET was prospectively performed in 44 patients with stage III or IV head and neck cancer. PET was performed twice during the first posttreatment year (at 2 and 10 months after therapy) and thereafter as needed. After therapy, patients were grouped, based on tissue biopsies, into those who achieved a complete response (CR) and those who had residual disease (RD). Patients who achieved a CR were further grouped into those without evidence of disease and those who had recurrence by I year after completion of therapy. Disease status as determined by physical examination (PE), PET, and correlative imaging was compared. Results: Eight patients were lost to follow-up and six had RD after therapy. Of the remaining 30 patients with a CR, 16 had recurrence in the first year after therapy. Five of these 16 patients had recurrence detected by PET only, four by PET and correlative imaging only, five by PE and PET only, and two by PE, correlative imaging, and PET. Only PET detected all recurrences in the first year. PET performed better than correlative imaging (P = .013) or PE (P = .002) in the detection of recurrence. Conclusion: PET can detect head and neck tumor recurrence when it may be undetectable by other clinical methods. FDG-PET permits highly accurate detection of head and neck cancer recurrence in the posttherapy period. (C) 2000 by American Society of Clinical Oncology.",
author = "Val Lowe and Boyd, {James H.} and Dunphy, {Frank R.} and Han Kim and T. Dunleavy and Collins, {Brian T.} and David Martin and Stack, {Brendan C.} and Chris Hollenbeak and Fletcher, {J. W.}",
year = "2000",
month = "2",
language = "English (US)",
volume = "18",
pages = "651--658",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Surveillance for recurrent head and neck cancer using positron emission tomography

AU - Lowe, Val

AU - Boyd, James H.

AU - Dunphy, Frank R.

AU - Kim, Han

AU - Dunleavy, T.

AU - Collins, Brian T.

AU - Martin, David

AU - Stack, Brendan C.

AU - Hollenbeak, Chris

AU - Fletcher, J. W.

PY - 2000/2

Y1 - 2000/2

N2 - Purpose: Earlier detection of head and neck cancer recurrence may improve survival. We evaluated the ability of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) to detect recurrence in a prospective trial using sequential PET scans. Patients and Methods: Serial posttherapy FDG-PET was prospectively performed in 44 patients with stage III or IV head and neck cancer. PET was performed twice during the first posttreatment year (at 2 and 10 months after therapy) and thereafter as needed. After therapy, patients were grouped, based on tissue biopsies, into those who achieved a complete response (CR) and those who had residual disease (RD). Patients who achieved a CR were further grouped into those without evidence of disease and those who had recurrence by I year after completion of therapy. Disease status as determined by physical examination (PE), PET, and correlative imaging was compared. Results: Eight patients were lost to follow-up and six had RD after therapy. Of the remaining 30 patients with a CR, 16 had recurrence in the first year after therapy. Five of these 16 patients had recurrence detected by PET only, four by PET and correlative imaging only, five by PE and PET only, and two by PE, correlative imaging, and PET. Only PET detected all recurrences in the first year. PET performed better than correlative imaging (P = .013) or PE (P = .002) in the detection of recurrence. Conclusion: PET can detect head and neck tumor recurrence when it may be undetectable by other clinical methods. FDG-PET permits highly accurate detection of head and neck cancer recurrence in the posttherapy period. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: Earlier detection of head and neck cancer recurrence may improve survival. We evaluated the ability of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) to detect recurrence in a prospective trial using sequential PET scans. Patients and Methods: Serial posttherapy FDG-PET was prospectively performed in 44 patients with stage III or IV head and neck cancer. PET was performed twice during the first posttreatment year (at 2 and 10 months after therapy) and thereafter as needed. After therapy, patients were grouped, based on tissue biopsies, into those who achieved a complete response (CR) and those who had residual disease (RD). Patients who achieved a CR were further grouped into those without evidence of disease and those who had recurrence by I year after completion of therapy. Disease status as determined by physical examination (PE), PET, and correlative imaging was compared. Results: Eight patients were lost to follow-up and six had RD after therapy. Of the remaining 30 patients with a CR, 16 had recurrence in the first year after therapy. Five of these 16 patients had recurrence detected by PET only, four by PET and correlative imaging only, five by PE and PET only, and two by PE, correlative imaging, and PET. Only PET detected all recurrences in the first year. PET performed better than correlative imaging (P = .013) or PE (P = .002) in the detection of recurrence. Conclusion: PET can detect head and neck tumor recurrence when it may be undetectable by other clinical methods. FDG-PET permits highly accurate detection of head and neck cancer recurrence in the posttherapy period. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0033966155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033966155&partnerID=8YFLogxK

M3 - Article

C2 - 10653881

AN - SCOPUS:0033966155

VL - 18

SP - 651

EP - 658

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -